The global immunoassays market is projected to reach USD 49.6 billion by 2027, growing at a CAGR of 4.3% during the forecast period from USD 40.2 billion in 2022. This growth is primarily driven by factors such as the increasing prevalence of chronic and infectious diseases, advancements in systems and technologies, and supportive government policies.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436
Leading players in this market include Abbott Laboratories, F. Hoffmann-La Roche, and Siemens Healthineers AG. These players dominate the market due to their extensive product portfolios. They have also employed organic strategies such as product launches and regulatory approvals, as well as inorganic growth strategies like collaborations, partnerships, acquisitions, and agreements to maintain their market shares.
Abbott Laboratories holds the largest market share of 20-25% in 2021. The company has a strong presence in the US and aims to expand its geographical reach in emerging markets. With a robust product portfolio and FDA- and CE Mark-approved products, including its Point-of-Care Diagnostic Afinion HbA1c Dx Assay for COVID-19 diagnostics, Abbott Laboratories has successfully maintained its market position.
F. Hoffmann-La Roche ranks second in the immunoassay market, capturing a share of 15-20% in 2021. The company’s leading position is attributed to its diverse product portfolio, encompassing clinical chemistry and immunochemistry solutions, molecular diagnostic products, tissue diagnostic instruments, reagents, and kits. Through its cobas brand, F. Hoffmann-La Roche offers a range of IVD instruments, reagents, and kits. With a broad geographic presence across North America, Europe, the Middle East & Africa, and Asia, the company focuses on product launches, partnerships, and collaborations to maintain its leadership position. The acquisition of GenMark Diagnostics in 2021 has further strengthened Roche’s diagnostics portfolio.
Siemens Healthineers holds the third-largest market share of 5.0-10.0% in the immunoassay market in 2021. The company has a direct presence in 70 countries and over 4,000 collaborations worldwide. With regional headquarters in the US and Germany and manufacturing sites across various countries, including the US, the UK, Germany, Spain, South Korea, China, and India, Siemens Healthineers is well-positioned in the market. The company’s focus on product development and launches has contributed to maintaining its market position. In response to the demand for COVID-19 diagnosis, Siemens Healthineers has introduced several immunoassay kits.
Drivers for market growth include the increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis. Immunoassay tests are essential diagnostic tools that provide reliable and cost-effective detection of pathogens or target molecules, making them crucial in containing and managing chronic diseases and the COVID-19 pandemic. The demand for early-stage disease diagnosis using immunoassay products is another significant factor driving market growth.
Opportunities lie in advancements in systems and technologies. Key players and researchers have developed advanced, reliable, and cost-effective immunoassay platforms for disease diagnostics. Automated systems offer scalability, high throughput, faster processing, extensive storage, and high efficacy, meeting the requirements for COVID-19 diagnosis and management.
Related Links
https://www.marketsandmarkets.com/Market-Reports/immunoassay-market-436.html
https://www.marketsandmarkets.com/PressReleases/immunoassay.asp
